Cargando…

All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease

AIMS: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden. METHODS: We tested whether ENFORCE, an established prediction model o...

Descripción completa

Detalles Bibliográficos
Autores principales: Copetti, Massimiliano, Biancalana, Edoardo, Fontana, Andrea, Parolini, Federico, Garofolo, Monia, Lamacchia, Olga, De Cosmo, Salvatore, Trischitta, Vincenzo, Solini, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164049/
https://www.ncbi.nlm.nih.gov/pubmed/34050821
http://dx.doi.org/10.1007/s00592-021-01746-2
_version_ 1783701032008679424
author Copetti, Massimiliano
Biancalana, Edoardo
Fontana, Andrea
Parolini, Federico
Garofolo, Monia
Lamacchia, Olga
De Cosmo, Salvatore
Trischitta, Vincenzo
Solini, Anna
author_facet Copetti, Massimiliano
Biancalana, Edoardo
Fontana, Andrea
Parolini, Federico
Garofolo, Monia
Lamacchia, Olga
De Cosmo, Salvatore
Trischitta, Vincenzo
Solini, Anna
author_sort Copetti, Massimiliano
collection PubMed
description AIMS: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden. METHODS: We tested whether ENFORCE, an established prediction model of all-cause mortality in type 2 diabetes, performs well also in two independent samples of patients with early-stage disease prospectively followed up. RESULTS: ENFORCE’s survival C-statistic was 0.81 (95%CI: 0.72–0.89) and 0.78 (95%CI: 0.68–0.87) in both samples. Calibration was also good. Very similar results were obtained with RECODe, an alternative prediction model of all-cause mortality in type 2 diabetes. CONCLUSIONS: In conclusion, our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-021-01746-2.
format Online
Article
Text
id pubmed-8164049
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Milan
record_format MEDLINE/PubMed
spelling pubmed-81640492021-06-01 All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease Copetti, Massimiliano Biancalana, Edoardo Fontana, Andrea Parolini, Federico Garofolo, Monia Lamacchia, Olga De Cosmo, Salvatore Trischitta, Vincenzo Solini, Anna Acta Diabetol Original Article AIMS: The rate of all-cause mortality is twofold higher in type 2 diabetes than in the general population. Being able to identify patients with the highest risk from the very beginning of the disease would help tackle this burden. METHODS: We tested whether ENFORCE, an established prediction model of all-cause mortality in type 2 diabetes, performs well also in two independent samples of patients with early-stage disease prospectively followed up. RESULTS: ENFORCE’s survival C-statistic was 0.81 (95%CI: 0.72–0.89) and 0.78 (95%CI: 0.68–0.87) in both samples. Calibration was also good. Very similar results were obtained with RECODe, an alternative prediction model of all-cause mortality in type 2 diabetes. CONCLUSIONS: In conclusion, our data show that two well-established prediction models of all-cause mortality in type 2 diabetes can also be successfully applied in the early stage of the disease, thus becoming powerful tools for educated and timely prevention strategies for high-risk patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00592-021-01746-2. Springer Milan 2021-05-29 2021 /pmc/articles/PMC8164049/ /pubmed/34050821 http://dx.doi.org/10.1007/s00592-021-01746-2 Text en © Springer-Verlag Italia S.r.l., part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Copetti, Massimiliano
Biancalana, Edoardo
Fontana, Andrea
Parolini, Federico
Garofolo, Monia
Lamacchia, Olga
De Cosmo, Salvatore
Trischitta, Vincenzo
Solini, Anna
All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
title All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
title_full All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
title_fullStr All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
title_full_unstemmed All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
title_short All-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
title_sort all-cause mortality prediction models in type 2 diabetes: applicability in the early stage of disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164049/
https://www.ncbi.nlm.nih.gov/pubmed/34050821
http://dx.doi.org/10.1007/s00592-021-01746-2
work_keys_str_mv AT copettimassimiliano allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease
AT biancalanaedoardo allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease
AT fontanaandrea allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease
AT parolinifederico allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease
AT garofolomonia allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease
AT lamacchiaolga allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease
AT decosmosalvatore allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease
AT trischittavincenzo allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease
AT solinianna allcausemortalitypredictionmodelsintype2diabetesapplicabilityintheearlystageofdisease